Artiva Biotherapeutics, Inc.
ARTV
$2.88
$0.113.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 251.00K | 2.60M | 29.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 251.00K | 2.60M | 29.26M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 0.00 | 251.00K | 2.60M | 29.26M |
| SG&A Expenses | 19.83M | 18.74M | 17.21M | 15.42M | 13.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.58M | 74.96M | 67.54M | 63.59M | 61.10M |
| Operating Income | -81.58M | -74.96M | -67.28M | -60.99M | -31.84M |
| Income Before Tax | -75.13M | -71.72M | -65.37M | -61.20M | -32.45M |
| Income Tax Expenses | -- | -- | -- | 72.00K | 72.00K |
| Earnings from Continuing Operations | -75.13 | -71.72 | -65.37 | -61.28 | -32.53 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.13M | -71.72M | -65.37M | -61.28M | -32.53M |
| EBIT | -81.58M | -74.96M | -67.28M | -60.99M | -31.84M |
| EBITDA | -79.07M | -72.49M | -64.85M | -58.58M | -29.50M |
| EPS Basic | -3.29 | -24.41 | -40.82 | -54.99 | -40.08 |
| Normalized Basic EPS | -2.53 | -15.73 | -25.99 | -43.87 | -34.56 |
| EPS Diluted | -3.95 | -25.08 | -41.49 | -69.81 | -67.27 |
| Normalized Diluted EPS | -2.53 | -15.73 | -25.99 | -43.87 | -42.28 |
| Average Basic Shares Outstanding | 92.00M | 68.44M | 44.90M | 21.33M | 3.24M |
| Average Diluted Shares Outstanding | 92.00M | 68.44M | 44.90M | 21.33M | 9.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |